Clinical trials: Aspiration, Respiratory
Healthy Volunteers, Safety
Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects
The purpose of the study is to assess safety and tolerability of AZD9819 following inhaled administration of single and multiple increasing doses, and to estimate the maximum dose that is tolerated in healthy people.
- Conditions
- Healthy Volunteers, Safety, Tolerability
- Trial name
- NCT01166698
- Testing
- AZD9819
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Adult Subject
Effect of Super-Oxygenated Water on Blood Oxygen Saturation
Therapeutic delivery of additional Oxygen to blood stream via hyperbaric and extracorporeal oxygenation that raises blood Oxygen saturation level, apart from oxygenation in the lungs, is known to induce tissue repair, restore…
- Trial name
- NCT07016191
- Testing
- Ingestion of Water
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Inhale, Inc
COPD
Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD
This is a phase 1/phase 2a, single dose, crossover study conducted in two parts. Part 1: Phase 1, open-label, 4-period crossover study in 8 healthy subjects to determine the optimal dose of AERO-001 and AERO-002, the active…
- Trial name
- NCT06841640
- Testing
- AERO-001, AERO-002, AERO-007
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AeroRx Therapeutics Inc.
Asthma
Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma
This is a Phase 1b, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetic profiles of voriconazole inhalation powder in adult subjects with well-controlled asthma.
- Trial name
- NCT04576325
- Testing
- Voriconazole Inhalation Powder
- Where
- Australia
- Volunteers
- 17 people
- Sponsor
- TFF Pharmaceuticals, Inc.
Asthma
Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old
The rationale is to investigate the systemic availability of BDP/B17MP and formoterol after single oral inhalation of CHF 1535 50/6 pMDI vs the free combination of approved BDP and Formoterol pMDIs, in asthmatic children (5 to 11…
- Trial name
- PAED1 (NCT01848769)
- Testing
- CHF1535 pMDI + AC Plus, BDP + AC Plus, Formoterol + AC Plus
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pneumonia
Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)
Study to demonstrate that administration of Venticute increases survival of patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygenation impairment.
- Trial name
- NCT00074906
- Testing
- Venticute
- Where
- 92 sites in Australia, Austria and 15 more
- Volunteers
- 1,200 people
- Sponsor
- Takeda
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease (COPD), Lung Disease Chronic, Lung Diseases, Obstructive
- Trial name
- AERODUO-2 (NCT07896252)
- Testing
- AERO-001, AERO-002, AERO-007
- Where
- 2 sites in United Kingdom
- Volunteers
- 64 people
- Sponsor
- AeroRx Therapeutics Inc.
Postoperative Sedation, Intubation
GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting
Patients who are in the intensive care unit after surgery and require mechanical breathing support (intubation and ventilation) usually require sedation to avoid agitation and excessive stress responses.
- Conditions
- Postoperative Sedation, Intubation, Respiration, Artificial
- Trial name
- NCT00125398
- Testing
- AQUAVAN (fospropofol disodium; GPI 15715 )
- Where
- 17 sites in United States
- Volunteers
- 60 people
- Sponsor
- Eisai Inc.
Aspiration Pneumonia
Functionality and Accuracy of the smART System in Real-Life ICU Settings
Total participants in the "Functionality and Accuracy of the smART System in Real-Life ICU Settings" are 10 participants - in the current Jefferson study site there were 8 participants and in the Sheba study site (identifier…
- Trial name
- NCT03198988
- Testing
- smART Feeding Tube System
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- ART Medical Ltd.
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
Upper Airway Obstruction, Respiratory Insufficiency
Astral VAPS AutoEPAP Clinical Trial
Patients with chronic respiratory failure such as those associated with Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS), Obstructive Sleep Apnea (OSA) or Neuromuscular Disease (NMD) are…
- Conditions
- Upper Airway Obstruction, Respiratory Insufficiency, Respiratory Failure
- Trial name
- NCT02683772
- Testing
- Astral
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- ResMed
Pulmonary Disease, Chronic Obstructive
ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times.
- Trial name
- NCT00144911
- Testing
- Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
- Where
- 97 sites in United States, Canada
- Volunteers
- 740 people
- Sponsor
- GlaxoSmithKline
Airway Obstruction, Sedation Complication
Medical Device for Airway Patency During Sedation
OVERALL SYNOPSIS PART A: Systematic evaluation in spontaneously breathing healthy volunteer study participants of cumulative duration of manual measures for airway patency and for mask ventilation with airway device prototype…
- Conditions
- Airway Obstruction, Sedation Complication, Perioperative Complication
- Trial name
- STAIRWAY-2 (NCT06270212)
- Testing
- STAIRWAY, NO DEVICE
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Stairway Medical AB
Electric Stimulation, Respiration, Artificial
Breath Synchronized Abdominal Muscle Stimulation to Facilitate Ventilator Weaning: a Pilot Study
The primary objective of this study is to determine whether neuromuscular electrical stimulation applied to the abdominal wall muscles in synchrony with exhalation can increase the strength of the respiratory muscles in prolonged…
- Conditions
- Electric Stimulation, Respiration, Artificial, Ventilator Weaning
- Trial name
- NCT03019107
- Testing
- Breath synchronized abdominal NMES
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Liberate Medical
Healty Babies, 3 Weeks - 3 Months Old
Baby Breathing Monitoring @Home
To give reassurance to parents, Philips would like to add algorithms to the NightOwl baby monitor to be able to measure baby behavior and physiology.
- Trial name
- NCT05175560
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- Philips Clinical & Medical Affairs Global
COVID-19
Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness
This is a Phase 1/2, randomized, double-blind, placebo-controlled, single-dose escalating-dose study in participants with mild to moderate COVID-19 illness.
- Trial name
- NCT05298813
- Testing
- IBIO123
- Where
- 11 sites in Brazil, South Africa
- Volunteers
- 162 people
- Sponsor
- Immune Biosolutions Inc
Ventilators, Mechanical, Stroke
Evaluation of VQm PHM on Pulmonary Health Parameters for ICU
The goal of this observational study is to compare pulmonary health parameter measurements from the VQm PHM™ to existing clinical measurements.
- Conditions
- Ventilators, Mechanical, Stroke, COPD, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT06147674
- Testing
- VQm Pulmonary Health Monitor™
- Where
- 4 sites in United States, Austria and 2 more
- Volunteers
- 150 people
- Sponsor
- Rostrum Medical Innovations Inc.
Pulmonary Arterial Hypertension
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis).
- Trial name
- NCT00741819
- Testing
- Inhaled treprostinil
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- United Therapeutics
Pulmonary Embolism Acute
Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness
The investigation is intended to evaluate the safety and effectiveness of the AlphaReturn Blood Management System when used in conjunction with the cleared AlphaVac MMA F1885 System for the treatment of acute pulmonary embolism.
- Trial name
- APEX-Return (NCT07280247)
- Testing
- AlphaReturn Blood Management System
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- Angiodynamics, Inc.
Healthy
AZD9164 Single Ascending Dose Study in Healthy Male Subjects
The aims of the study are to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD9164 following single ascending dose administrations to healthy male subjects.
- Trial name
- NCT00847249
- Testing
- AZD9164
- Where
- Sweden
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- AstraZeneca